Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.

@article{Furuta2002EffectOC,
  title={Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.},
  author={T Furuta and Naohito Shirai and Fumitoshi Watanabe and Satoru Honda and Ken Takeuchi and Takayuki Iida and Yoshihiko Sato and Masayoshi Kajimura and Hajime Futami and Shigekazu Takayanagi and Masami Yamada and Kyoichi Ohashi and Takashi Ishizaki and Hiroyuki Hanai},
  journal={Clinical pharmacology and therapeutics},
  year={2002},
  volume={72 4},
  pages={453-60}
}
BACKGROUND AND OBJECTIVES The acid-inhibitory effect of lansoprazole depends on differences in cytochrome P450 (CYP) 2C19 genotypes. We assessed whether therapeutic effects of lansoprazole on gastroesophageal reflux disease (GERD) depended on the CYP2C19 genotype status in relation to the grade of GERD. METHODS A total of 65 patients with GERD (grades A-D) completed treatment with lansoprazole, by taking 30 mg orally once a day for 8 weeks. The CYP2C19 genotype status of patients was… CONTINUE READING